Expert Review of Pharmacoeconomics & Outcomes Research最新文献_第5页

Preference research is underutilized in health prevention. 偏好研究在健康预防方面未得到充分利用。

IF 1.5 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-08-17 DOI: 10.1080/14737167.2025.2548279

Brett Hauber, Mickael Hiligsmann

引用次数: 0

Cost-effectiveness analysis of cenobamate for epilepsy patients with drug-resistant focal onset seizures in the Netherlands. cenobamate治疗荷兰耐药局灶性癫痫患者的成本-效果分析

IF 1.5 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-08-10 DOI: 10.1080/14737167.2025.2542280

Nannan Li, Marian Majoie, Silvia Evers, Kim Rijkers, Felix Gubler, Rob Rouhl, Richard Lazeron, Pim Klarenbeek, Vicki Laskier-Owens, Mickaël Hiligsmann

{"title":"Cost-effectiveness analysis of cenobamate for epilepsy patients with drug-resistant focal onset seizures in the Netherlands.","authors":"Nannan Li, Marian Majoie, Silvia Evers, Kim Rijkers, Felix Gubler, Rob Rouhl, Richard Lazeron, Pim Klarenbeek, Vicki Laskier-Owens, Mickaël Hiligsmann","doi":"10.1080/14737167.2025.2542280","DOIUrl":"10.1080/14737167.2025.2542280","url":null,"abstract":"Objective: To assess the cost-effectiveness of cenobamate in epileptic people with focal seizures in the Netherlands.Methods: A Markov model was used to simulate lifetime costs and quality-adjusted life years (QALYs) for cenobamate compared to perampanel, brivaracetam, and lacosamide from the Dutch societal perspective. Data from a randomized controlled trial and open-label extension were used to determine the transition probability, efficacy and safety of treatment with cenobamate. Treatment, administration, routine monitoring, seizure event management, adverse events and productivity costs were included. Both one-way and probabilistic sensitivity analyses were conducted to explore the uncertainty.Results: Cenobamate was associated with an average total cost of €466,560 and 9.922 QALY gained. Among the four drugs tested, treatment with cenobamate indicated lowest cost and highest QALY gained, suggesting cenobamate dominates all comparators. One-way sensitivity analysis confirms the robustness of our results. Probabilistic sensitivity analyses revealed that at the willingness to pay threshold of €50,000/QALY, the probability that cenobamate is cost-effective was 100%.Conclusion: With the acknowledgment of the limitations, we concluded that cenobamate is less costly and more effective, which can be considered a cost-effective treatment option for patients with drug-resistant focal seizures in the Netherlands. Future real-world data are needed to confirm our findings.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1-13"},"PeriodicalIF":1.5,"publicationDate":"2025-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144768574","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cost-utility analysis of Lenvatinib vs. Sorafenib in unresectable hepatocellular carcinoma in Iran. Lenvatinib和Sorafenib在伊朗不可切除的肝细胞癌中的成本-效用分析。

IF 1.5 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-08-07 DOI: 10.1080/14737167.2025.2543465

Mohammad Mahdi Raeis Zadeh, Behzad Fatemi, Neshaut Mashreghi Mohammadi, Fatemeh Soleymani

{"title":"Cost-utility analysis of Lenvatinib vs. Sorafenib in unresectable hepatocellular carcinoma in Iran.","authors":"Mohammad Mahdi Raeis Zadeh, Behzad Fatemi, Neshaut Mashreghi Mohammadi, Fatemeh Soleymani","doi":"10.1080/14737167.2025.2543465","DOIUrl":"10.1080/14737167.2025.2543465","url":null,"abstract":"Background: Hepatocellular carcinoma (HCC) is a global health issue and the third leading cause of cancer-related deaths. For patients with unresectable HCC (uHCC), Sorafenib and Lenvatinib, are key treatments. This study evaluates the cost-effectiveness of Lenvatinib versus Sorafenib for uHCC in Iran.Research design and methods: A model-based cost-utility analysis was conducted using a Partitioned Survival Analysis (PartSA) model from the perspective of the Iranian society. Clinical data were sourced from the REFLECT trial, while cost inputs, including treatment, monitoring, and side-effect management, were derived from local healthcare data and expert consultations. Sensitivity analyses and Monte Carlo simulations ensured robustness.Results: The base-case analysis revealed that Lenvatinib, with a total cost of $9,607, offers a cost saving of $1,551 compared to Sorafenib ($11,158). Lenvatinib also provides an incremental gain of 0.14 Quality-Adjusted Life Years (QALYs) per patient over a 20-years. Probabilistic sensitivity analysis showed a > 99% probability of Lenvatinib being cost-effective. One-way analysis confirmed Lenvatinib's cost-effectiveness if priced below $18/day.Conclusions: Lenvatinib is a cost-effective alternative to Sorafenib for uHCC treatment in Iran, providing better clinical outcomes and cost savings. These results support its adoption as the preferred treatment, emphasizing the importance of integrating cost-effectiveness analyses into healthcare decision-making.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1-8"},"PeriodicalIF":1.5,"publicationDate":"2025-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144774979","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cost-effectiveness of MRI strategies for early prostate cancer detection: a systematic review. 早期前列腺癌MRI检测策略的成本效益：一项系统综述。

IF 1.5 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-08-07 DOI: 10.1080/14737167.2025.2543464

Asal Sadat Niaraees Zavare, Atefeh Najafi Shahkoohi, Farhad Khalili, Aziz Rezapour, Somayeh Afshari, Samira Alipour, Ali Sarabi Asiabar

{"title":"Cost-effectiveness of MRI strategies for early prostate cancer detection: a systematic review.","authors":"Asal Sadat Niaraees Zavare, Atefeh Najafi Shahkoohi, Farhad Khalili, Aziz Rezapour, Somayeh Afshari, Samira Alipour, Ali Sarabi Asiabar","doi":"10.1080/14737167.2025.2543464","DOIUrl":"10.1080/14737167.2025.2543464","url":null,"abstract":"Objectives: The objective of this study is to evaluate the cost-effectiveness of different Magnetic Resonance Imaging strategies for the early detection of prostate cancer.Methods: A comprehensive search was conducted up to 15 December 2024, utilizing databases such as PubMed and Scopus. The focus was on full economic evaluations, excluding non-English articles and reviews. The quality of the studies was assessed using the QHES checklist. The following data were extracted: settings, interventions, populations, types of economic evaluations, health outcomes, costs, and ICERs.Results: Of the 110 articles that were assessed, 9 were selected for qualitative analysis, resulting in an overall high-quality score. The findings demonstrated that the range of MRI costs applied differed across countries. While the financial implications of non-screening are comparatively lower, the effectiveness of using screening strategies for early detection of cancer is superior to that of non-screening. Specifically, MRI was found to be more cost-effective than conventional methods. The utilization of MRI prior to biopsy has the potential to reduce unnecessary procedures while enhancing clinical cancer detection.Conclusion: The economic viability of integrating advanced MRI techniques into prostate cancer screening is demonstrated, leading to enhanced patient outcomes by facilitating early detection and minimizing overtreatment.Registration: PROSPERO (CRD42024572261).","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1-14"},"PeriodicalIF":1.5,"publicationDate":"2025-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144783900","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Health and economic impact of 20-valent pneumococcal conjugate vaccine for adults aged 66-84 years in Japan and Shiga prefecture. 20价肺炎球菌结合疫苗对日本和滋贺县66-84岁成人的健康和经济影响

IF 1.5 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-07-28 DOI: 10.1080/14737167.2025.2519755

Tomoyuki Suzuki, Yoko Hirano, Kazumasa Kamei, Kayoko Miyata, Masahiro Kusama, Piotr Karwala, Camille Moyon, Catriona Crossan, Shuhei Ito, Jeffrey Vietri, Fumihiko Kakuno

{"title":"Health and economic impact of 20-valent pneumococcal conjugate vaccine for adults aged 66-84 years in Japan and Shiga prefecture.","authors":"Tomoyuki Suzuki, Yoko Hirano, Kazumasa Kamei, Kayoko Miyata, Masahiro Kusama, Piotr Karwala, Camille Moyon, Catriona Crossan, Shuhei Ito, Jeffrey Vietri, Fumihiko Kakuno","doi":"10.1080/14737167.2025.2519755","DOIUrl":"10.1080/14737167.2025.2519755","url":null,"abstract":"Background: The Japanese National Immunization Program against pneumococcal disease (PD) includes 23-valent pneumococcal polysaccharide vaccine (PPSV23) but does not provide vaccination for adults aged ≥66 years. We evaluated the cost-effectiveness of 20-valent pneumococcal conjugate vaccine (PCV20) in adults aged 66-84 years with no history of PPSV23 vaccination in Japan and assessed the potential economic and health impact of introducing PCV20 on the local government (specifically, Shiga prefecture).Research design and methods: Using a Markov model, we assessed lifetime costs, quality-adjusted life-years (QALYs), and number of prevented cases and deaths caused by PD.Results: In national-level analysis, PCV20 was cost-effective compared with no vaccination under incremental cost-effectiveness ratio threshold of Japanese yen (JPY) 5,000,000/QALY, i.e. JPY1,677,401/QALY and JPY1,351,811/QALY from payer and societal perspectives, respectively. PCV20 was dominant (less costly and more effective) compared with PPSV23. In local-level analysis, the introduction of PCV20 required initial costs but resulted in greater cost savings related to medical expenses (-JPY424 and -JPY430 per person) and nursing care (-JPY560 and -JPY575 per person) compared to PPSV23 and no vaccination, respectively.Conclusions: PCV20 is cost-effective compared with PPSV23 and no vaccination in adults aged 66-84 years, which could reduce the future healthcare burden in Japan.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1-14"},"PeriodicalIF":1.5,"publicationDate":"2025-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144283153","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Multicenter, cross-sectional study of the economic burden of multiple sclerosis and cost-driving factors. 多发性硬化症的经济负担和成本驱动因素的多中心横断面研究。

IF 1.8 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-07-24 DOI: 10.1080/14737167.2025.2539840

Moustafa Berrichi, Zahira Barka-Bedrane, Ahlam Osmani, Karima Belahcen, Bouchra Hafsi, Ines Messaoudi, Mohammed Adil Selka, Houari Toumi

{"title":"Multicenter, cross-sectional study of the economic burden of multiple sclerosis and cost-driving factors.","authors":"Moustafa Berrichi, Zahira Barka-Bedrane, Ahlam Osmani, Karima Belahcen, Bouchra Hafsi, Ines Messaoudi, Mohammed Adil Selka, Houari Toumi","doi":"10.1080/14737167.2025.2539840","DOIUrl":"https://doi.org/10.1080/14737167.2025.2539840","url":null,"abstract":"Background: Multiple sclerosis (MS) is a chronic neurodegenerative disease impacting young adults, reducing quality of life and imposing economic burdens.Objectives: This study estimated MS costs in Algeria from a societal perspective, analyzed cost variations by disease severity, and provided insights for enhancing MS management and healthcare planning.Methods: A cross-sectional, bottom-up cost-of-illness study used a validated questionnaire to collect demographic, clinical, and socioeconomic data from MS patients. Data included disease-modifying therapy (DMT) use, MS course, and EDSS scores. Direct costs (medical and non-medical) and indirect costs (productivity losses from absenteeism and early retirement) were calculated. Cost drivers were analyzed using generalized linear models.Results: Among 354 patients, the total annual societal cost per MS patient was $9,636.5 (95% CI: 9101.2 -10,178), with a mean EDSS score of 3.1 (SD 2.1). Direct costs accounted for 93.31%, with DMTs comprising 94.42% of direct medical costs. Costs rose with disease severity, from $8,697.9 (95% CI: 8060.9-9326.8) for mild MS to $12,450.8 (95% CI: 10137.2 -14,773.6) for severe MS (p < 0.001).Conclusions: This study highlights MS's economic burden in Algeria, with DMTs as the primary cost driver. Optimized resource allocation and cost-effective DMT strategies are essential to improve MS care.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144698002","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Switching hemophilia A patients to an extended half-life agent on a prophylactic basis: an economic appraisal. 在预防的基础上将血友病患者转换为延长半衰期的药物：经济评估。

IF 1.8 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-07-12 DOI: 10.1080/14737167.2025.2532805

Konstantinos Drakos, Ariston Karagiorgis, Olga Katsarou, Efrosyni Nomikou, Sofia Vakalopoulou, Marina Economou, Helen Pergantou

{"title":"Switching hemophilia A patients to an extended half-life agent on a prophylactic basis: an economic appraisal.","authors":"Konstantinos Drakos, Ariston Karagiorgis, Olga Katsarou, Efrosyni Nomikou, Sofia Vakalopoulou, Marina Economou, Helen Pergantou","doi":"10.1080/14737167.2025.2532805","DOIUrl":"10.1080/14737167.2025.2532805","url":null,"abstract":"Background: Gaining an understanding of transitioning hemophilia patients to an extended half-life (EHL) agent requires real-world data, encompassing various outcomes, which would help assessing the impact of the switch, for patients and the healthcare system. We investigate the economic implications of switching from standard half-life (SHL) recombinant factor VIII (rFVIII) from either prophylaxis or on-demand, to EHL rFVIII efmoroctocog alfa (FVIIIFc) prophylaxis.Research design and methods: The study involved 48 patients with hemophilia A from the 5 specialized hemophilia centers in Greece. Patients switched from prophylactic or on-demand treatment using a SHL factor VIII to a rFVIIIFc on prophylaxis only. Data was gathered for the 12-month period before and after switch. Using standard t-tests and regression analysis, we compared the direct treatment cost between the pre and post switch time, focusing on regimens' differential costs.Results: There is no statistically significant cost increase compared to the core rFVIII regimen used before the switch, when only patients that were previously on prophylaxis were considered. However, there is a statistically significant reduction in cost across treatment styles.Conclusions: The analysis confirms the advantages offered by prophylaxis with rFVIIIFc from an economic standpoint for the Greek healthcare system, in accordance with other studies.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1-8"},"PeriodicalIF":1.8,"publicationDate":"2025-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144599867","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cost-effectiveness of ruxolitinib in Singapore for patients with chronic graft-versus-host disease. 鲁索利替尼在新加坡治疗慢性移植物抗宿主病患者的成本效益

IF 1.8 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-07-07 DOI: 10.1080/14737167.2025.2529366

Naren Kumar Surendra, Jiamin Ong, Xin Yi Wong, Michelle Poon, Lydia Loke, Liang Lin, Mohamed Ismail Abdul Aziz, Benjamin Shao Kiat Ong, Kwong Ng

{"title":"Cost-effectiveness of ruxolitinib in Singapore for patients with chronic graft-versus-host disease.","authors":"Naren Kumar Surendra, Jiamin Ong, Xin Yi Wong, Michelle Poon, Lydia Loke, Liang Lin, Mohamed Ismail Abdul Aziz, Benjamin Shao Kiat Ong, Kwong Ng","doi":"10.1080/14737167.2025.2529366","DOIUrl":"10.1080/14737167.2025.2529366","url":null,"abstract":"Objective: To evaluate the cost-effectiveness of ruxolitinib in Singapore for patient with chronic graft-versus-host disease (GVHD) and inadequate response to corticosteroids.Methods: A three-state partitioned survival model was developed to evaluate the cost-effectiveness of ruxolitinib from the Singapore healthcare system perspective over a five-year time horizon. Clinical data were sourced from the REACH3 trial, health state utilities were retrieved from literature, and direct costs were obtained from public healthcare institutions in Singapore. Sensitivity and scenario analyses were conducted to explore the impact of uncertainties and assumptions on the cost-effectiveness results.Results: Compared to best available therapy, ruxolitinib yielded a base-case incremental cost-effectiveness ratio (ICER) of S$776,653 (US$574,724) per quality-adjusted life-years gained. Sensitivity analyses revealed that the ICER was particularly sensitive to utilities in failure-free and progressed disease states. Scenario analyses confirmed that the ICERs remained high even under favorable assumptions, and a substantial price reduction was necessary to lower the ICER.Conclusion: At its current price, ruxolitinib is not cost-effective for treating chronic GVHD in Singapore. This finding helps to inform funding decision-making, which also considers other factors such as clinical effectiveness, safety, and budget impact, in addition to cost-effectiveness.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1-8"},"PeriodicalIF":1.8,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144539753","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Transdisciplinary health economics for 2050: the challenge of preventing the adverse health effects of obesity, inequalities, and climate change. 2050年的跨学科卫生经济学：预防肥胖、不平等和气候变化对健康不利影响的挑战。

IF 1.8 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-07-01 Epub Date: 2025-05-01 DOI: 10.1080/14737167.2025.2498658

Rhiannon Tudor Edwards

引用次数: 0

Disease burden estimates in economic evaluation studies of respiratory syncytial virus (RSV) maternal immunization: a systematic review. 呼吸道合胞病毒（RSV）孕产妇免疫经济评价研究中的疾病负担估算：系统综述

IF 1.8 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-07-01 Epub Date: 2025-05-14 DOI: 10.1080/14737167.2025.2498663

Sophia Aguiar Monteiro Borges, Natacha Regina de Moraes Cerchiari, Erick Ohanesian Polli, Ana Carolina Nonato, Felipe Lima Barreto, Alexandre de Oliveira Esteves, Maarten Jacobus Postma, Ana Marli Christovam Sartori, Patrícia Coelho de Soárez

{"title":"Disease burden estimates in economic evaluation studies of respiratory syncytial virus (RSV) maternal immunization: a systematic review.","authors":"Sophia Aguiar Monteiro Borges, Natacha Regina de Moraes Cerchiari, Erick Ohanesian Polli, Ana Carolina Nonato, Felipe Lima Barreto, Alexandre de Oliveira Esteves, Maarten Jacobus Postma, Ana Marli Christovam Sartori, Patrícia Coelho de Soárez","doi":"10.1080/14737167.2025.2498663","DOIUrl":"10.1080/14737167.2025.2498663","url":null,"abstract":"Introduction: Recently, new technologies have emerged for the prevention of respiratory syncytial virus (RSV) infections. Reliable epidemiological data are essential for accurately assessing the disease burden and informing health economic evaluations (HEE). This review evaluates how HEE of RSV maternal vaccination (MV) estimated the RSV disease burden.Methods: A systematic search was conducted in MEDLINE, SCOPUS, EMBASE, NHS EED, HTA, Tufts CEA Registry, LILACS, and Web of Science for full HEE of RSV MV. Reporting quality was assessed with the CHEERS 2022 checklist, costs were converted to 2024 U.S. dollars, and a descriptive, interpretive synthesis of the data was performed.Results: All 21 included studies were cost-utility analyses, 10 conducted in high-income countries. The HEE utilized a wide range of data sources to build epidemiological estimates, frequently relying on non-local data, particularly for outpatient rates. National data on RSV hospitalization rates were the most commonly available. No study included equity assessments. The maternal vaccine dose price was identified as a critical factor in the strategy's cost-effectiveness.Conclusion: Enhancing local data availability for RSV, by strengthening the respiratory virus surveillance, is crucial to improve the reliability of HEE of RSV prevention strategies and enable more informed and effective policy decisions.Registration: PROSPERO: CRD42024549989.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"863-896"},"PeriodicalIF":1.8,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143960070","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0